Haemonetics (NYSE: HAE) director awarded 2,538 RSUs vesting in one year
Rhea-AI Filing Summary
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Martin D. Madaus received a grant of 2,538 restricted stock units under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on July 24, 2026. The RSUs vest 100% on the first anniversary of the grant date, with each unit delivering one share of common stock and 2,538 shares reported as directly owned after the award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,538 shares
Net Buy
1 txn
Insider
Madaus Martin D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Holdings After Transaction:
Common Stock — 2,538 shares (Direct)
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
RSU grant size: 2,538 units
Shares following award: 2,538 shares
Vesting schedule: 100% after 1 year
+1 more
4 metrics
RSU grant size
2,538 units
Restricted stock units awarded to director on July 24, 2026
Shares following award
2,538 shares
Total common shares reported as directly owned after the transaction
Vesting schedule
100% after 1 year
RSUs vest 100% on the first anniversary of the grant date
RSU-to-share ratio
1 RSU : 1 share
Each RSU is a contingent right to receive one share of common stock
Key Terms
restricted stock units ("RSUs"), contingent right, Long-Term Incentive Compensation Plan
3 terms
restricted stock units ("RSUs") financial
"The securities awarded are in the form of restricted stock units ("RSUs")"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents a contingent right to receive one (1) share"
Long-Term Incentive Compensation Plan financial
"pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity award did Haemonetics (HAE) director Martin D. Madaus receive?
He received 2,538 restricted stock units (RSUs) as a director equity award. The RSUs were granted under Haemonetics Corporation’s Amended and Restated 2019 Long-Term Incentive Compensation Plan and represent future shares of common stock once vested.
When do the 2,538 RSUs granted to Haemonetics (HAE) director Martin D. Madaus vest?
The RSUs vest 100% on the first anniversary of the grant date. This means all 2,538 units are scheduled to vest in a single tranche one year after July 24, 2026, if vesting conditions are satisfied.
What does each RSU granted to Haemonetics (HAE) director Martin D. Madaus represent?
Each RSU represents a contingent right to receive one share of Haemonetics common stock. When the RSUs vest, they convert into an equivalent number of common shares, delivered one-for-one.
Was the Haemonetics (HAE) insider equity grant made under a Rule 10b5-1 trading plan?
The transaction was not affirmed as made under a Rule 10b5-1 plan. The Rule 10b5-1 checkbox associated with this insider report was left unchecked, indicating no such plan affirmation.